Evidence outlook
Approved: Rheumatoid Arthritis, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (4)
- Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).
- Pemphigus Vulgaris (PV) RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.
- Adult patients with Non-Hodgkin's Lymphoma (NHL)
- MabThera (rituximab) for rheumatoid arthritis, in combination with methotrexate, severe active RA after inadequate response to other DMARDs including TNF inhibitors
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00468546 NCT00468546 · Rheumatoid Arthritis The REFLEX phase 3 trial: randomized, double-blind, placebo-controlled, 520 participants with rheumatoid arthritis who had failed anti-TNF therapy, all on background methotrexate. The primary endpoint, ACR20 response at week 24, was reached by 153 of 298 participants on rituximab (51.3%) versus 36 of 201 on placebo (17.9%). ClinicalTrials.gov records no statistical analysis for the comparison, but a 33-percentage-point difference on a validated clinical response endpoint at this sample size is arithmetically undeniable, so the primary is read as met (significance inferred from counts). Registry: NCT00468546 | 3 | Number of Participants With American College of Rheumatology 20 Response at Week 24 2005-01 | ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate. | Reliable signal | link ↗ |
View 3 more trials
SUNRISE NCT00266227 · Rheumatoid Arthritis The retreatment phase was randomized, double-blind, and placebo-controlled, with 318 participants receiving rituximab retreatment and 157 receiving placebo, and its clinical ACR20 primary endpoint was met. However, no power calculation is reported in the available record, so the evidence is rated moderate despite the favorable result. Registry: NCT00266227 | 3 | Retreated Subjects With an American College of Rheumatology 20% (ACR20) Response at Week 48 Relative to Baseline (48 Weeks) 2007-10 | Retreated Subjects With an American College of Rheumatology 20% (ACR20) Response at Week 48 Relative to Baseline (48 Weeks): Arm A: Rituximab Retreatment 170/318 (53.5%) vs Arm B: Placebo Retreatment 70/157 (44.6%) | Partial signal | link ↗ |
IMAGE NCT00299104 · Rheumatoid Arthritis Randomized, double-blind, placebo-controlled trial in 755 patients with X-ray joint damage at week 52 as the primary endpoint. Rituximab 2 x 1.0 g plus methotrexate significantly reduced joint damage progression compared with methotrexate alone, but rituximab 2 x 0.5 g did not, so the primary result was only partly met. Registry: NCT00299104 | 3 | Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52 (Baseline and week 52) 2008-09 | Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52 (Baseline and week 52): Rituximab (0.5 g x 2) + Methotrexate 0.646 Score on a scale (Standard Deviation 1.9196) | Rituximab (1.0 g x 2) + Methotrexate 0.359 Score on a scale (Standard Deviation 1.0095) vs Placebo + Methotrexate 1.079 Score on a scale (Standard Deviation 4.0934) | Partial signal | link ↗ |
SERENE NCT00299130 · Rheumatoid Arthritis Patients were randomly assigned to rituximab (two doses) or placebo, all on background methotrexate, with patients and investigators blinded. The trial enrolled the number of patients its power calculation required (at least 167 per arm), and both rituximab doses beat placebo on the primary measure, ACR20 response at week 24 (p<0.0001). Registry: NCT00299130 | 3 | Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24) 2008-06 | Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3% | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (288)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (48)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (959)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (239)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (280)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (85)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (79)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (130)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (76)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (28)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Studied as part of a combination product (10)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 3 (1)
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (62)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (33)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other CD20 drugs
Obinutuzumab, Ocrelizumab, Ocrevus Zunovo, Ofatumumab, PF-05280586 and 10 more. Compare all 16 CD20 drugs
This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rituximab (Rituxan): this drug | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Acalabrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Approved | Small molecule | BTK | Partial signal | NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62) | |
| Obinutuzumab | Approved | Monoclonal antibody | CD20 | Partial signal | No reviewed efficacy summary in this indication | |
| Ocrelizumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ocrevus Zunovo | Approved(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ofatumumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Pirtobrutinib | Approved | Small molecule | BTK | Partial signal | Featured results are non-efficacy only in this race | |
| Rituximab-Abbs (Truxima) | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Venetoclax | Approved | Small molecule | BCL-2 | Partial signal | NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001) | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | Partial signal | NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results). | |
| ABP 692 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BCD-281 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bexobrutideg | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P53 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Nemtabrutinib | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 2/3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1/2 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(321 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rituxan (Rituximab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.